Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma

 Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma

 Shots:

  • The REFLECTIONS B328-06 study involves assessing of PF-05280586 vs Rituxan/MabThera (rituximab) in patients with 1L CD20-positive, low tumor burden, follicular lymphoma evaluating its efficacy, safety and immunogenicity, PK and PD
  • The study demonstrated meeting of 1EPs as OS @26 wks. (75.5% vs 70.7%) and PFS@ 1yrs (76.4% vs 81.2%) with similar safety & efficacy to MabThera
  • PF-05280586 (rituximab biosimilar) is an mAb, indicated for CD20-positive chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis and microscopic polyangiitis and other region-specific indications of and is currently reviewed by the US FDA with expected BsUFA date in H2’19

Click here to read full press release/ article | Ref: Pfizer | Image: Market Exclusive

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post